ViiV Healthcare
 |
|
| Type | Joint venture |
|---|---|
| Industry | Healthcare |
| Founded | November 2009 |
| Headquarters | Brentford, United Kingdom |
| Area served | Global |
| Key people | Dominique Limet |
| Products | Pharmaceuticals |
| Website | http://www.viivhealthcare.com/ |
ViiV Healthcare is a pharmaceutical company specializing in the development of therapies for HIV that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company.[1] 85% of the company is owned by GlaxoSmithKline with the remaining 15% owned by Pfizer. This ownership structure may change depending upon the achievement of certain milestones.[1]
ViiV Healthcare's products have a market share of approximately 19 percent[2] of the global HIV market, which makes it the second largest health care company, following after Gilead Sciences, that is working on the treatment of HIV.[3]
ViiV Healthcare's headquarters are in Brentford in the United Kingdom and it has sites in a number of other countries including; the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[4]
Contents |
[edit] Products
The company currently markets 10 products:[5][6]
- Combivir
- Epivir
- Epzicom/Kivexa
- Lexiva/Telzir
- Rescriptor
- Retrovir
- Selzentry/Celsentri
- Trizivir
- Viracept
- Ziagen
[edit] Treatment access programs
ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This supplies all of its therapies at cost price to 64 countries.[7]
The company has also granted voluntary licenses to eight generics companies to enable the low cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[8] [9]
[edit] Criticisms
The foundation of ViiV Healthcare has been criticized by Treatment Action Group which had suspicions about the motives behind Pfizer and GlaxoSmithKline's desire to form the new company. The group's concerns centered on the possibility that the two pharmaceutical companies were using ViiV Healthcare as a way to get out of a field of research that has not been particularly commercially successful.[1]
[edit] See also
[edit] References
- ^ a b c Jacks, Andrew "GSK and Pfizer to merge HIV portfolios Financial Times. April 16, 2010
- ^ "ViiV company website - about us" Accessed October 13 2010
- ^ Jacks, Andrew "ViiV vows joint venture will help fight HIV" Financial Times. November 3, 2009
- ^ "ViiV company website - about us" Accessed October 13 2010
- ^ "ViiV company website - products" Accessed October 13, 2010
- ^ McNeil, Donald "AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease" New York Times. November 9, 2009
- ^ ViiV company website - not for profit pricing Accessed 13 October, 2010
- ^ ViiV company website - voluntary licensing Accessed 13 October, 2010
- ^ Reuters "Glaxo, Pfizer JV opens HIV pipeline to generic companies" Africa - the good news, July 19, 2010
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
